1. WHO should continue its efforts in strengthening international guidelines for registration of generic drugs.
2. In collaboration with Member States, WHO should continue to focus on activities related to good trade and distribution practices of starting materials to assure the use of high quality materials.
3. WHO should work with other technical partners, within the concept of a global alliance, to improve the quality of products moving in international commerce.
4. WHO should establish a pre-qualification quality assurance system for essential medicines.
5. WHO should continue its prequalification project for procurement of medicines for priority diseases.
6. In collaboration with Member States, WHO should develop additional international guidance on important elements of combination medicines focusing on rational use to maximize the benefit in specific disease treatment.
7. Governments and drug regulatory authorities should encourage the development of therapies for neglected diseases through incentives, co-operative efforts and public/private initiatives.
8. Progress should be reported back to the ICDRA.